200 related articles for article (PubMed ID: 17671722)
1. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells.
Hamacher R; Saur D; Fritsch R; Reichert M; Schmid RM; Schneider G
Oncol Rep; 2007 Sep; 18(3):695-701. PubMed ID: 17671722
[TBL] [Abstract][Full Text] [Related]
2. Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by down-regulation of casein kinase 2 in prostate cancer cells.
Ahmad KA; Wang G; Ahmed K
Mol Cancer Res; 2006 May; 4(5):331-8. PubMed ID: 16687488
[TBL] [Abstract][Full Text] [Related]
3. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
Schneider CC; Hessenauer A; Montenarh M; Götz C
Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
[TBL] [Abstract][Full Text] [Related]
4. Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine.
Yamane K; Kinsella TJ
Clin Cancer Res; 2005 Mar; 11(6):2355-63. PubMed ID: 15788687
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.
Di Maira G; Brustolon F; Bertacchini J; Tosoni K; Marmiroli S; Pinna LA; Ruzzene M
Oncogene; 2007 Oct; 26(48):6915-26. PubMed ID: 17486073
[TBL] [Abstract][Full Text] [Related]
6. CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation.
Yamane K; Kinsella TJ
Cancer Res; 2005 May; 65(10):4362-7. PubMed ID: 15899828
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells.
Hessenauer A; Montenarh M; Götz C
Int J Oncol; 2003 Jun; 22(6):1263-70. PubMed ID: 12738992
[TBL] [Abstract][Full Text] [Related]
8. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
9. Casein Kinase II: an attractive target for anti-cancer drug design.
Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
[TBL] [Abstract][Full Text] [Related]
10. Validation of protein kinase CK2 as oncological target.
Seeber S; Issinger OG; Holm T; Kristensen LP; Guerra B
Apoptosis; 2005 Aug; 10(4):875-85. PubMed ID: 16133877
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of AG1109 on recombinant human protein kinase CK2 holoenzyme].
Liu XG; Liang NC
Ai Zheng; 2002 Feb; 21(2):153-7. PubMed ID: 12479065
[TBL] [Abstract][Full Text] [Related]
12. [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme].
Li CM; Liu XG; Lin XC; Chen XW; Liang NC
Ai Zheng; 2008 Aug; 27(8):809-15. PubMed ID: 18710613
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
[TBL] [Abstract][Full Text] [Related]
14. [Protein kinase CK2 and cancer: further clues are accumulating].
Filhol O; Cochet C
Bull Cancer; 2002 Mar; 89(3):261-5. PubMed ID: 11940465
[TBL] [Abstract][Full Text] [Related]
15. Resorufin: a lead for a new protein kinase CK2 inhibitor.
Sandholt IS; Olsen BB; Guerra B; Issinger OG
Anticancer Drugs; 2009 Apr; 20(4):238-48. PubMed ID: 19177021
[TBL] [Abstract][Full Text] [Related]
16. p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2.
Martel V; Filhol O; Colas P; Cochet C
Oncogene; 2006 Nov; 25(56):7343-53. PubMed ID: 16751801
[TBL] [Abstract][Full Text] [Related]
17. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
18. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Kazimierczuk Z; Grieb P; Stepien H
Cell Tissue Res; 2010 May; 340(2):371-9. PubMed ID: 20383646
[TBL] [Abstract][Full Text] [Related]
19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
20. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.
Melstrom LG; Salabat MR; Ding XZ; Milam BM; Strouch M; Pelling JC; Bentrem DJ
Pancreas; 2008 Nov; 37(4):426-31. PubMed ID: 18953257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
